MorphoSys

The T-cell malignancies market is expanding due to increased incidence, treatment advancements, and strategic partnerships. Key companies like Corvus Pharmaceuticals, Bristol-Myers Squibb, and Kymera Therapeutics are developing over 80 pipeline therapies. Notable drugs include Soquelitinib (Phase III), MB 105 (Phase II), and KT-333 (Phase I). Regulatory milestones and positive trial results are driving progress in this field.

Pfizer's earnings beat expectations amid Starboard criticism; Novartis delays submission for MorphoSys drug; Biogen appoints new chief medical officer; VCs use U.S. startups to hedge bets on Chinese drugs; GSK acquires autoimmune drug candidate; key figures in cancer vaccine development; Medicare's drug price negotiations explained.

Novartis raises full-year operating profit forecast to high teens growth, citing strong drug sales. CEO Vas Narasimhan delays submission of a rare bone marrow cancer drug to regulators by a couple more years due to unresolved data profile issues.

Roche ends Alzheimer’s partnership with UCB, returning rights to Phase 2a candidate bepranemab. This marks Roche's third Alzheimer’s candidate termination this year, following similar actions with AC Immune. Despite setbacks, Roche remains active in early Alzheimer’s diagnosis.

FDA grants Biogen's monoclonal antibody felzartamab breakthrough therapy designation for treating late antibody-mediated rejection in kidney transplant patients, based on positive Phase II trial data. Biogen plans to initiate Phase III trials for felzartamab in multiple indications next year. The therapy, acquired through the $1.15bn HI-Bio acquisition, is expected to generate over $776m by 2032 if approved.

Biogen's felzartamab receives FDA Breakthrough Therapy Designation for treating late antibody-mediated rejection in kidney transplant patients. Biogen plans to initiate Phase 3 trials in 2025 across AMR, IgAN, and PMN. Originally developed by MorphoSys for multiple myeloma, felzartamab's rights were exclusively licensed to HI-Bio, acquired by Biogen in July 2024.

Biogen's felzartamab receives FDA Breakthrough Therapy Designation for treating late antibody-mediated rejection in kidney transplant patients. Biogen plans Phase 3 trials in 2025 for AMR, IgAN, and PMN. Originally developed by MorphoSys for multiple myeloma, felzartamab was licensed by HI-Bio, acquired by Biogen in 2024.